What is BCRX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.18B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BCRX?

P/E (TTM) is n/a and 52-week range is $6.00 to $11.22 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BCRX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BCRX?

The company profile lists revenue (TTM) near $902M, net income (TTM) near $-36.87B, EPS (TTM) near $-1.50 when available from the market-data feed. Figures are informational and may lag live markets.

Where is BioCryst Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Durham, North Carolina, US, 254.2M shares outstanding, ISIN US09058V1035 when available from company profile and filing metadata.

Chartloom

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 435 full-time employees. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. The company has also obtained an early-stage program for atopic dermatitis, STAR0310.

Employees

435

Website

www.biocryst.com/

IPO

1994-03-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)